GlassScriptPhysician profile
Natalia Ramirez
NPI 1255086971
$6,434.21
in general payments reported to CMS, 2019-2025
21 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,056 · 2023: $2,181 · 2024: $1,337 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,297 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,296.93 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,306.83 | 2022-2025 | Spravato, Invega Sustenna, Xarelto |
| Abbvie INC. | $815.12 | 2022-2025 | |
| Alkermes, INC. | $681.33 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $674.68 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $525.28 | 2022-2025 | Caplyta |
| Corium, LLC | $319.73 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $316.18 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $294.03 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $287.51 | 2022-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $260.04 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Idorsia Pharmaceuticals US INC | $197.71 | 2022-2024 | Quviviq |
| Lundbeck LLC | $187.54 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $133.25 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $129.01 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $127.09 | 2023-2025 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $47.64 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $40.71 | 2024 | |
| Supernus Pharmaceuticals, INC. | $32.40 | 2022-2023 | Qelbree |
| Noven Therapeutics, LLC | $22.60 | 2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $20.11 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.